|
|||||
|
|
Hybrid compounds as new Bcr/Abl inhibitors |
|
| Authors: | Wang Deping Zhang Zhang Lu Xiaoyun Feng Yubing Luo Kun Gan Jirong Yingxue Liu Wan Junting Li Xiang Zhang Fengxiang Tu Zhengchao Cai Qian Ren Xiaomei Ding Ke |
| Institution: | a Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No.190, Kaiyuan Avenue, Science Park, Guangzhou 510530, China b Graduate School of Chinese Academy of Sciences, # 19 Yuquan Road, Beijing 100049, China |
| Abstract: | A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs. |
| Keywords: | 2 4-Disubstituted thiazole Hybride compound Bcr/Abl kinase Chronic myelogenous leukemia Anticancer |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |